Outcome of Intercostal Tube Insertion and Pleurodesis for Malignant Pleural Effusion
| Registry | NCT06742099 |
|---|---|
| Status | Not yet recruiting |
| Phase | Early Phase 1 |
| Study type | Interventional; randomized, single group, masking: none, treatment |
| Enrollment | 20 (Estimated) |
| Sponsor | Assiut University (Other) |
| Conditions | Malignant Pleural Effusions (Mpe) |
| Interventions | Intercostal chest tube, Pleurodesis (Procedure, combination product) |
| Dates | start 2024-12-30 (estimated), primary completion 2025-06-15 (estimated), completion 2025-09-30 (estimated), first posted 2024-12-19, last updated 2024-12-19 |
| Locations | 1 site in Egypt |
Related Papers Related Patents Related Grants Related Experts
All trials for Malignant Pleural Effusions (Mpe) All trials of Intercostal chest tube All trials of Pleurodesis
Approximately half of all patients with metastatic cancer develop a malignant pleural effusion which is likely to lead to a significant reduction in quality of life secondary to symptoms such as dyspnoea and cough. The aim of pleurodesis in these patients is to prevent re-accumulation of the effusion and thereby of symptoms,and avoid the need for repeated hospitalization for thoracocentesis. Numerous clinical studies have been performed to try to determine the optimal pleurodesis strategy, and synthesis of the available evidence should facilitate this. The treatment of MPE is aimed at palliating symptoms since no intervention has been shown to improve survival in this population and since survival is generally limited in cancers that have spread to the pleural space. In this palliative setting, only patients symptomatic from their MPE should be submitted to further intervention. As well, further interventions in symptomatic patients should be limited to those patients who have experienced symptomatic improvement following initial therapeutic thoracentesis. The two main treatment approaches to MPE are to obliterate the pleural space via a pleurodesis procedure or to chronically drain the pleural cavity with Intercostal tube. The aims of this review were to ascertain the optimal procedure in cases of malignant pleural effusion in terms of patients' quality of life post procedure, recurrence of effusion.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Malignant Pleural effusion with pleurodesis | Active comparator | Procedure: Intercostal chest tube; Combination Product: Pleurodesis | these are patients who have malignant pleural effusion and will have talc injected into the pleural cavity to induce pleurodesis |
| Malignant Pleural effusion with only chest tube for drainage | Active comparator | Procedure: Intercostal chest tube | these are patients who have malignant pleural effusion but will only have intercostal chest tube inserted for drainage |
Sex: All
Inclusion Criteria: * All patients presented with malignant pleural effusion to Assiut University Hospital regardless of sex and age Exclusion Criteria: * All patients presented with pleural effusion other than malignant pleural effusion, including patients with debilitating diseases and terminal patients.
| Facility | City | Country | Status |
|---|---|---|---|
| Assiut University Hospital | Asyut, Asyut Governorate | Egypt |